Corcept Therapeutics (CORT)

Generated: October 31, 2026

Green Dot

Statistics

Metric	Value
Last Close	$72.70
Blended Price Target	104.46
Blended Margin of Safety	43.7% Undervalued
Rule of 40 (Next)	69.0%
Rule of 40 (Current)	74.5%
FCF-ROIC	23.5%
Sales Growth Next Year	45.5%
Sales Growth Current Year	51.0%
Sales 3-Year Avg	28.8%
Industry	Biotechnology

Analysis

Corcept is a high-quality commercial-stage biotechnology business with an unusually strong combination of an established endocrine franchise, expanding oncology exposure, and a credible late-stage pipeline. Second-quarter 2026 revenue reached $256.1 million, up 32% year over year, with the newly launched Lifyorli adding meaningful diversification alongside continued Korlym and authorized-generic revenue.^[3] The growth outlook is therefore more durable than that of a single-product biotech, although it remains exposed to regulatory execution and concentration in cortisol-modulating therapies.

Revenue is fundamentally prescription-driven rather than contractual, but demand is relatively predictable because patients require ongoing treatment and Corcept has built specialized physician and payer infrastructure. Its moat is narrower than that of a diversified pharmaceutical company, yet meaningful in Cushing’s syndrome: clinical expertise, accumulated evidence, physician familiarity, and regulatory know-how reinforce the franchise. Leadership has demonstrated disciplined development and commercialization, but the next stage will test its ability to launch Lifyorli, secure approval for relacorilant, and manage a broader portfolio without losing focus.

What the Company Does

Corcept develops and commercializes medicines that modulate cortisol, a hormone implicated in endocrine, oncologic, metabolic, and neurologic diseases. Its first commercial product, Korlym, treats hyperglycemia secondary to endogenous Cushing’s syndrome; revenue comes primarily from prescriptions filled through specialty-pharmacy and payer channels.

The business gained a second commercial product in 2026 when the FDA approved Lifyorli, or relacorilant, with nab-paclitaxel for platinum-resistant ovarian cancer. In the second quarter, Korlym and its authorized generic generated $208.6 million, while Lifyorli contributed $47.6 million in its first quarter of availability.^[3] The mix is shifting from a largely endocrine business toward a broader endocrine-oncology platform.

Revenue Recurrence & Predictability

Corcept’s revenue is transactional at the point of prescription fulfillment, not subscription-based or supported by long-term customer contracts. Nevertheless, it has recurring characteristics because Cushing’s syndrome is chronic, treatment interruptions can be clinically consequential, and established patients may continue therapy for extended periods.

Predictability is strongest in the existing Korlym franchise, where physician relationships, reimbursement processes, and patient-support programs can support repeat demand. Lifyorli is less predictable because it depends on oncology treatment decisions, combination use, commercial adoption, and competitive positioning. No current company disclosure identified a precise percentage of revenue that is recurring or highly predictable.

Revenue Growth Durability

Corcept still appears to have substantial room to expand in both Cushing’s syndrome and cortisol-sensitive cancers. Growth can come from diagnosing more patients, improving treatment persistence, broadening physician awareness, expanding payer coverage, and increasing use of Lifyorli in its approved ovarian-cancer setting. Management also resubmitted relacorilant’s Cushing’s syndrome application in June 2026, with an FDA decision expected by December 17, 2026.^[3]

The principal structural tailwind is the company’s ability to apply one pharmacologic expertise across diseases with significant unmet need. The principal headwinds are limited disease populations, diagnostic under-recognition, reimbursement friction, clinical-trial setbacks, and dependence on successful regulatory outcomes. Above-market growth looks realistic for several years if Lifyorli scales and relacorilant is approved, but the trajectory will likely be uneven rather than linear.

Economic Moat

Corcept’s strongest advantages are intangible rather than physical. It has specialized knowledge of cortisol biology, clinical-development experience in difficult-to-diagnose disorders, proprietary clinical data, and established relationships with endocrinologists, oncologists, payers, and specialty pharmacies. These assets can reduce execution risk and make physician adoption easier than for an unproven entrant.

Switching costs are moderate for physicians and patients because treatment changes may require new authorization, monitoring, or clinical reassessment, but they are not insurmountable. Network effects and manufacturing cost advantages appear limited. The moat is potentially widening through Lifyorli commercialization and additional cortisol-related indications, although it could narrow if competing therapies offer superior efficacy, safety, convenience, or reimbursement terms.

Management & Leadership

Corcept’s leadership has deep continuity. CEO Joseph Belanoff co-founded the company and has led it since its formation, giving the business founder-level strategic consistency and extensive knowledge of its science and commercial model. The company’s progress from Korlym to an oncology launch and a resubmitted relacorilant application indicates sustained development and commercialization capability.

Recent public materials did not provide a sufficiently current, precise insider-ownership percentage for this analysis. Capital allocation has primarily supported clinical development, regulatory work, commercial infrastructure, and business operations rather than a diversified acquisition strategy. That focus fits the company’s specialized platform but increases dependence on internal execution.

Key Risks

The most immediate risk is regulatory and clinical. Relacorilant’s approval is not assured after the prior complete response letter, and any further delay could postpone a major expansion of the Cushing’s franchise. Lifyorli must also demonstrate durable adoption in a competitive ovarian-cancer market where treatment decisions depend on evolving clinical evidence.

Commercial concentration remains significant. Even after Lifyorli’s launch, Korlym and its authorized generic supplied most second-quarter revenue, leaving Corcept exposed to payer pressure, generic competition, prescription disruption, and changes in treatment guidelines.^[3] A small number of indications and a focused commercial infrastructure magnify the consequences of an unexpected setback.

Operationally, Corcept must scale oncology capabilities while preserving its specialized endocrine support model. Manufacturing, pharmacovigilance, reimbursement access, and physician education become more demanding as the portfolio expands. Broader macroeconomic conditions matter less than industry-specific risks, particularly regulatory scrutiny, clinical-trial execution, competing cortisol-modulating medicines, and the possibility that new indications prove smaller or harder to commercialize than expected.

Sources

Featured in GreenDot Stocks Analysis

GreenDot Stocks Screen Update — Week of November 7, 2026 November 7, 2026
GreenDot Stocks Screen Update — Week of October 31, 2026 October 31, 2026
GreenDot Stocks Screen Update — Week of October 24, 2026 October 24, 2026
GreenDot Stocks Screen Update — Week of October 17, 2026 October 17, 2026
GreenDot Stocks Screen Update — Week of October 10, 2026 October 10, 2026